Small Lymphocytic Lymphoma (DBCOND0023538)

Identifiers

Synonyms
Lymphoma, Lymphocytic, Small / B-cell Small Lymphocytic Lymphoma (SLL) / B-cell small lymphocytic lymphoma / B-cell small lymphocytic lymphomas / SLL (Small Lymphocytic Lymphoma) / SLL / Small Lymphocytic Lymphoma (SLL) / Small lymphocytic lymphoma / Small cell lymphocytic lymphoma / Small lymphocyte B lymphoma (Lukes-Collins Classification) / B-cell small lymphocytic lymphoma NOS / Malignant lymphoma, small lymphocytic (morphologic abnormality) / Malignant lymphoma - small lymphocytic (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Acalabrutinib
A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.
Ibrutinib
An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.
Pirtobrutinib
A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy.
Venetoclax
A BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia.
Zanubrutinib
A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerNot AvailableNot Availableavailable
NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignanciestreatment1completed
NCT01500733
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)treatment3recruiting
NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLtreatment1 / 2completed
NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLLtreatment2terminated
NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLLNo drug interventionstreatment1withdrawn
NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemiatreatment1terminated
NCT04704323
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic LeukemiaNo drug interventionstreatment1recruiting
NCT02046928
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment2terminated
NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLtreatment1 / 2terminated
NCT04694560
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaNo drug interventionsNot AvailableNot Availablewithdrawn
NCT02863692
Registry of the German CLL Study GroupNo drug interventionsNot AvailableNot Availablerecruiting
NCT00980395
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphomatreatment2completed
NCT04419519
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclaxtreatment2recruiting
NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphomatreatment1 / 2active_not_recruiting
NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNo drug interventionstreatment1recruiting
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TNo drug interventionsother1enrolling_by_invitation
NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's LymphomaNo drug interventionstreatment1terminated
NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesNo drug interventionstreatment1unknown_status
NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2recruiting
NCT03406156
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapytreatment3completed
NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLtreatment1recruiting
NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)treatment2withdrawn
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignanciestreatment1 / 2active_not_recruiting
NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLtreatment2terminated
NCT03788291
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT00694590
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1completed
NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomatreatment1 / 2completed
NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaNo drug interventionstreatment1 / 2terminated
NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment2active_not_recruiting
NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNo drug interventionstreatment1recruiting
NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNo drug interventionstreatment1recruiting
NCT05168930
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)treatment2recruiting
NCT05708326
A Case Crossover Study of Intermittent Fasting in CLL/SLLNo drug interventionspreventionNot Availablecompleted
NCT03702231
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)basic_science2completed
NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignanciestreatment1 / 2completed
NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesNo drug interventionstreatment1completed
NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphomatreatment1terminated
NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)treatment1 / 2recruiting
NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)treatment1terminated
NCT01181271
Tandem Auto-Allo Transplant for Lymphomatreatment2completed
NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)treatment2terminated
NCT00143065
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT00083473
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemiatreatment2terminated
NCT00060684
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphomatreatment1completed
NCT00081809
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphomatreatment2completed
NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T CellsNo drug interventionsNot AvailableNot Availablerecruiting
NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLNot AvailableNot Availableterminated
NCT02292225
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)treatment1terminated
NCT02677948
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1 / 2withdrawn
NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomastreatment2completed
NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carrierstreatment3unknown_status
NCT04626843
Intermittent Fasting and CLL/SLLNo drug interventionstreatment1completed
NCT03420183
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignanciestreatment1 / 2recruiting
NCT00923507
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)No drug interventionsNot AvailableNot Availablerecruiting
NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)treatment3enrolling_by_invitation
NCT02048813
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3active_not_recruiting
NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrometreatment2recruiting
NCT03701282
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemiatreatment3active_not_recruiting
NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemiatreatment3completed
NCT03737981
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemiatreatment3active_not_recruiting
NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Studytreatment3recruiting
NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumabtreatment1 / 2completed
NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomastreatment1 / 2terminated
NCT04666038
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT05479994
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)treatment3recruiting
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)treatment3recruiting
NCT06544785
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT02135133
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLtreatment2completed
NCT04624633
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLtreatment2active_not_recruiting
NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplanttreatment2recruiting
NCT05317936
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclaxtreatment2active_not_recruiting
NCT05521178
Cardiotoxicities in Patients Receiving BTKiNo drug interventionsNot AvailableNot Availablewithdrawn
NCT06291220
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment1recruiting
NCT01496976
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLtreatment2active_not_recruiting
NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLtreatment1 / 2recruiting
NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHLtreatment1 / 2active_not_recruiting
NCT04623541
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrometreatment1 / 2recruiting
NCT05602363
AS-1763 in Patients with Previously Treated CLL/SLL or Non-Hodgkin LymphomaNo drug interventionstreatment1recruiting
NCT06636175
64Cu-LLP2A for Imaging Hematologic MalignanciesNo drug interventionsdiagnostic0not_yet_recruiting
NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemiatreatment2recruiting
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLtreatment1 / 2active_not_recruiting
NCT06520098
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment2not_yet_recruiting
NCT05336812
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemiatreatment2recruiting
NCT05388006
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2not_yet_recruiting
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT01306643
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphomatreatment1 / 2completed
NCT01722487
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLLtreatment3completed
NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLtreatment3active_not_recruiting
NCT06364033
Biological and Clinical Efficacy of Shingrix in Patients With CLLNo drug interventionsbasic_scienceNot Availablenot_yet_recruiting
NCT01000753
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaNo drug interventionsNot AvailableNot Availablecompleted
NCT01105247
Safety of PCI-32765 in Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancerstreatment1 / 2terminated
NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseasestreatment2recruiting
NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesNo drug interventionstreatment1completed
NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphomatreatment2 / 3terminated
NCT02514083
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLtreatment2active_not_recruiting
NCT00100711
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT01161511
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemiatreatment1completed
NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment3recruiting
NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersNo drug interventionstreatment1recruiting
NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Diseasetreatment2active_not_recruiting
NCT01578707
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment3completed
NCT04771507
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)treatment1 / 2recruiting
NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35treatment2terminated
NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLtreatment1completed
NCT02049515
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07treatment3completed
NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)treatment2withdrawn
NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropeniatreatment1completed
NCT04867915
Study on the Diagnosis and Management of CLL in Italy by GIMEMANo drug interventionsNot AvailableNot Availablerecruiting
NCT01113632
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1completed
NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphomatreatment2terminated
NCT01239875
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphomatreatment0completed
NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)treatment1 / 2active_not_recruiting
NCT04176913
Study of LUCAR-20S in Patients With R/R NHLNo drug interventionstreatment1terminated
NCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT02296918
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLtreatment1active_not_recruiting
NCT05677919
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemiatreatment2recruiting
NCT03516617
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2recruiting
NCT02784834
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLtreatment1terminated
NCT01682616
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1completed
NCT01497496
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment2completed
NCT01351896
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT01292135
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT02661035
Allo HSCT Using RIC for Hematological Diseasestreatment2completed
NCT01364363
Unrelated Donor Stem Cell TransplantationNo drug interventionstreatmentNot Availablecompleted
NCT04852822
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNo drug interventionsNot AvailableNot Availableterminated
NCT04560322
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLtreatment2recruiting
NCT01832922
BR in Patients With CLL With Comorbidities and/or Renal Dysfunctiontreatment1completed
NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNo drug interventionstreatment1recruiting
NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemiaprevention2recruiting
NCT06367374
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLtreatment2not_yet_recruiting
NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersNo drug interventionstreatment2recruiting
NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomastreatment1active_not_recruiting
NCT00201682
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphomatreatment1 / 2completed
NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignanciestreatment2completed
NCT00439231
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .No drug interventionstreatment1 / 2recruiting
NCT01419691
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT02086591
A Phase II Study of Doxycycline in Relapsed NHLtreatment2terminated
NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT02337829
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLtreatment2active_not_recruiting
NCT03892044
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphomatreatment1completed
NCT04155840
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2terminated
NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignanciestreatment1 / 2withdrawn
NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.No drug interventionstreatment1recruiting
NCT04722172
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLtreatment2active_not_recruiting
NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT05718869
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Studytreatment2recruiting
NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplanttreatment3completed
NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLtreatment1 / 2completed
NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomastreatment2completed
NCT04504708
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesNo drug interventionstreatment1 / 2terminated
NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemiatreatment2recruiting
NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemiatreatment1 / 2active_not_recruiting
NCT00759603
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemiatreatment2completed
NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLtreatment1 / 2recruiting
NCT01611090
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3completed
NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantationtreatment2active_not_recruiting
NCT05287984
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLtreatment2not_yet_recruiting
NCT01173679
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLtreatment2terminated
NCT01973387
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphomatreatment3completed
NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitortreatment1withdrawn
NCT00974233
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLtreatment2completed
NCT05183854
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trialtreatment2recruiting
NCT04505254
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemiatreatment2recruiting
NCT04094051
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeNot AvailableNot Availableunknown_status
NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT01862445
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsNo drug interventionsNot AvailableNot Availableunknown_status
NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesNo drug interventionstreatment2terminated
NCT02756897
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemiatreatment2active_not_recruiting
NCT02910583
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)treatment2completed
NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesNo drug interventionstreatment1recruiting
NCT03422393
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinibtreatment1active_not_recruiting
NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemiatreatment1terminated
NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignanciestreatment1 / 2active_not_recruiting
NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLtreatment1terminated
NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyNo drug interventionstreatmentNot Availablerecruiting
NCT02629809
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemiatreatment2active_not_recruiting
NCT01145209
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLtreatment2completed
NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignanciestreatment1terminated
NCT03370185
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphomatreatment2withdrawn
NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)prevention2completed
NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignanciestreatment1completed
NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)treatment3withdrawn
NCT01117142
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersNo drug interventionsNot AvailableNot Availablecompleted
NCT01217749
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLtreatment1 / 2completed
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasestreatmentNot Availablerecruiting
NCT02825836
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjectstreatment1 / 2active_not_recruiting
NCT02529813
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignanciestreatment1completed
NCT05272813
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLLNo drug interventionstreatment1 / 2terminated
NCT04578613
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLtreatment3recruiting
NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomastreatment2completed
NCT00849524
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment2terminated
NCT01241786
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLtreatment2terminated
NCT02004522
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)treatment3completed
NCT06466122
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKitreatment2recruiting
NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphomatreatment2active_not_recruiting
NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553treatment1 / 2terminated
NCT03801525
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)treatment2 / 3terminated
NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)treatment1terminated
NCT03828448
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphomatreatment2terminated
NCT00873457
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2completed
NCT00850057
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1completed
NCT01754857
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLtreatment2completed
NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomatreatment2withdrawn
NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphomatreatment2completed
NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patientsprevention2terminated
NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignanciestreatment2completed
NCT03035331
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphomatreatment1 / 2active_not_recruiting
NCT00535873
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Oldertreatment2completed
NCT01650727
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)treatment1completed
NCT01239394
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphomatreatment2completed
NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphomatreatment1recruiting
NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemiatreatment2recruiting
NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphomatreatment2terminated
NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomatreatment1 / 2completed
NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancerstreatment1active_not_recruiting
NCT06547944
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)treatment1active_not_recruiting
NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLtreatment2recruiting
NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomastreatment1active_not_recruiting
NCT04843904
Safe Accelerated Venetoclax Escalation in CLLtreatment1recruiting
NCT00290004
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1 / 2completed
NCT01010568
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)treatment2terminated
NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemiatreatment2completed
NCT01724346
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment3completed
NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignanciestreatment1terminated
NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLtreatment2recruiting
NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLtreatment1 / 2active_not_recruiting
NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKitreatment2completed
NCT00234481
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemiatreatment1terminated
NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.treatment3completed
NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaNo drug interventionstreatment1terminated
NCT02518555
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphomasupportive_care3completed
NCT03019055
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellNo drug interventionstreatment1completed
NCT01002755
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT04682808
A Study of FCN-338 in Patients With Chronic CLL/SLLNo drug interventionstreatment1active_not_recruiting
NCT05371808
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:No drug interventionsNot AvailableNot Availablerecruiting
NCT04994587
Study of LUCAR-20S in Patients With R/R NHLNo drug interventionstreatment1recruiting